Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background: The Aspergillus Galactomannan Lateral Flow Assay (LFA) is a rapid test for the diagnosis of invasive aspergillosis (IA) that has been almost exclusively evaluated in patients with hematologic malignancies. An automated digital cube reader that allows for quantification of results has recently been added to the test kits. Methods: We performed a retrospective multicenter study on bronchoalveolar lavage fluid (BALF) samples obtained from 296 patients with various underlying diseases (65% without underlying hematological malignancy) who had BALF galactomannan (GM) ordered between 2013 and 2019 at the University of California, San Diego, the Medical University of Graz, Austria, and the Mannheim University Hospital, Germany. Results: Cases were classified as proven (n = 2), probable (n = 56), putative (n = 30), possible (n = 45), and no IA (n = 162). The LFA showed an area under the curve (AUC) of 0.865 (95% confidence interval [CI] .815–.916) for differentiating proven/probable or putative IA versus no IA, with a sensitivity of 74% and a specificity of 83% at an optical density index cutoff of 1.5. After exclusion of GM as mycological criterion for case classification, diagnostic performance of the LFA was highly similar to GM testing (AUC 0.892 vs 0.893, respectively). LFA performance was consistent across different patient cohorts and centers. Conclusions: In this multicenter study the LFA assay from BALF demonstrated good diagnostic performance for IA that was consistent across patient cohorts and locations. The LFA may serve a role as a rapid test that may replace conventional GM testing in settings where GM results are not rapidly available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“Aspergillus species cause over 300°000 cases of invasive aspergillosis (IA) annually, with a mortality rate ranging from 30 to 80% [1, 2].”
BackgroundSchauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommers, D., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30274-1 · Cited by 886
Aspergillus PCR: One Step Closer to Standardization
White, P. L., Bretagne, S., Klingspor, L., Melchers, W. J. G., McCulloch, E., Schulz, B., Finnstrom, N., Mengoli, C., Barnes, R. A., Donnelly, J. P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01767-09 · Cited by 296
Hoenigl, M., Prattes, J., Spiess, B., Wagner, J., Prueller, F., Raggam, R. B., Posch, V., Duettmann, W., Hoenigl, K., Wölfler, A., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.00467-14 · Cited by 233 · cited 1×
“Other molecular tests such as polymerase chain reaction (PCR) are also used [16, 17] but lack standardization [18] and have variable diagnostic performance across studies and settings [19, 20], particularly in the diagnosis of breakthrough infections [21] and in settings that use mold-active prophylaxis [22, 23].”
MethodSelf-citationWhite, P. L., Wingard, J. R., Bretagne, S., Löffler, J., Patterson, T. F., Slavin, M. A., Barnes, R. A., Pappas, P. G., & Donnelly, J. P. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ507 · Cited by 193
Breakthrough invasive fungal infections: Who is at risk?
Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses · doi:10.1111/myc.13148 · Cited by 191
Self-citationD'Haese, J., Theunissen, K., Vermeulen, E., Schoemans, H., De Vlieger, G., Lammertijn, L., Meersseman, P., Meersseman, W., Lagrou, K., & Maertens, J. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06423-11 · Cited by 186
Diagnosing COVID-19-associated pulmonary aspergillosis
Verweij, P. E., Gangneux, J.-P., Bassetti, M., Brüggemann, R. J. M., Cornely, O. A., Koehler, P., Lass-Flörl, C., van de Veerdonk, F. L., Chakrabarti, A., & Hoenigl, M. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30027-6 · Cited by 181
Self-citationHeldt, S., Prattes, J., Eigl, S., Spiess, B., Flick, H., Rabensteiner, J., Johnson, G., Prüller, F., Wölfler, A., Niedrist, T., et al. (2018) · Journal of Infection · doi:10.1016/j.jinf.2018.05.001 · Cited by 110
Self-citationJenks, J. D., Mehta, S. R., Taplitz, R., Law, N., Reed, S. L., & Hoenigl, M. (2019) · Journal of Infection · doi:10.1016/j.jinf.2018.10.014 · Cited by 54 · cited 1×
“Test strips were than inserted into the sample running buffer aliquot and results read after 30 minutes based on the manufacturers recommendations, as described before [24, 25, 27, 32].”
MethodSelf-citation
Cited by
Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
Self-citationHoenigl, M., Salmanton-García, J., Walsh, T. J., Nucci, M., Neoh, C. F., Jenks, J. D., Lackner, M., Sprute, R., Al-Hatmi, A. M. S., Bassetti, M., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30784-2 · Cited by 470
Self-citationLet’s talk about sex characteristics—as a risk factor for invasive fungal diseases.
Egger, M., Hoenigl, M., Thompson, G. R., Carvalho, A., & Jenks, J. D. (2022) · Mycoses · doi:10.1111/myc.13449 · Cited by 82
Self-citationAn update on current and novel molecular diagnostics for the diagnosis of invasive fungal infections
Jenks, J. D., White, P. L., Kidd, S. E., Goshia, T., Fraley, S. I., Hoenigl, M., & Thompson, G. R. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2267977 · Cited by 61
Self-citationFungal infections in immunocompromised critically ill patients
Garnacho-Montero, J., Barrero-García, I., & León-Moya, C. (2024) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2024.01.005 · Cited by 56
Metadata
- Authors
- Jenks, J. D., Prattes, J., Frank, J., Spiess, B., Mehta, S. R., Boch, T., Buchheidt, D., & Hoenigl, M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-31
- Volume
- 73
- Issue
- 7
- Pages
- e1737-e1744
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3081777061
- Cited by
- 77
- References
- 10
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. https://app.cochat.ai/papers/10.1093/cid/ciaa1281
- The paper
- Jenks, J. D., Prattes, J., Frank, J., Spiess, B., Mehta, S. R., Boch, T., Buchheidt, D., & Hoenigl, M. (2021). Performance of the Bronchoalveolar Lavage Fluid Aspergillus Galactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1281
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.